Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Mirror Biologics, Merck KGaA Collaborate on Metastatic Colorectal Cancer
Details : The collaboration aims to conduct a Phase II to evaluate the combination of an experimental immunotherapy drug, AlloStim, and an immune checkpoint inhibitor, Bavencio avelumab from Merck.
Product Name : AlloStim
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 08, 2025